Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 4 1

Status

Completed 5Not yet recruiting 3Terminated 2Recruiting 2

Sponsor Class

INDUSTRY 5NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Other solid neoplasm 5

Conditions

Neoplasms 1905Breast Neoplasms 1425Carcinoma, Non-Small-Cell Lung 1178Prostatic Neoplasms 740Colorectal Neoplasms 686Neoplasm Metastasis 623Multiple Myeloma 548Melanoma 529Ovarian Neoplasms 456Lung Neoplasms 447Lymphoma, Non-Hodgkin 385Lymphoma 374Recurrence 373Leukemia, Myeloid, Acute 370Pancreatic Neoplasms 358Carcinoma, Renal Cell 339Carcinoma, Hepatocellular 286Stomach Neoplasms 281Leukemia, Lymphocytic, Chronic, B-Cell 268Lymphoma, Follicular 254Head and Neck Neoplasms 246Glioblastoma 220Leukemia 215Small Cell Lung Carcinoma 183Lymphoma, Large B-Cell, Diffuse 183Squamous Cell Carcinoma of Head and Neck 181Urinary Bladder Neoplasms 175Carcinoma 175Uterine Cervical Neoplasms 174Advanced Solid Tumors 161

Interventions

sacituzumab govitecan 1bintrafusp alfa protein, human 1avelumab 1Gemcitabine 1DOXO-EMCH 1(2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Metastatic Solid Tumors × Clear all
NCT04457778 2026-05-04

First in Human Study of M6223

EMD Serono

Phase 1 Completed
58 enrolled 38 charts
Other solid neoplasm

Metastatic Solid Tumors

NCT04319198 2025-09-30

Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy

Gilead Sciences

Phase 4 Completed
25 enrolled 15 charts
Other solid neoplasm

Metastatic Solid Tumors

NCT00878423 2024-08-02

Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors

Astex Pharmaceuticals, Inc.

Phase 1 Completed
62 enrolled
Other solid neoplasm

Metastatic Solid Tumors

NCT03523390 2024-02-23

Phase I/Ib Multiple Ascending Dose Study in China

Merck KGaA, Darmstadt, Germany

Phase 1 Completed
24 enrolled 24 charts
Other solid neoplasm

Metastatic Solid Tumors

NCT02235688 2022-02-10

Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors

ImmunityBio, Inc.

Phase 1 Completed
30 enrolled
Other solid neoplasm

Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡